Literature DB >> 1712664

Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation.

L C Tao1.   

Abstract

From January 1976 to May 1990, 1673 patients with a liver mass or masses detected by imaging techniques underwent percutaneous fine-needle aspiration biopsy of the liver. Of these, 99 were diagnosed cytologically as "hepatocellular carcinoma" and 9 as "consistent with liver cell adenoma." The cytologic diagnoses were confirmed in the follow-up of all cases. Among the 99 patients with hepatocellular carcinoma, 3 had taken oral contraceptives for a period of 10, 11, and 12 years, respectively. The nine patients with liver cell adenoma were all users of oral contraceptives over a period ranging from 5 to 10 years. Of these, two who had taken oral contraceptives for a period of 8 and 10 years, respectively, had foci or areas of liver cell dysplasia within the adenomas. The cytologic criteria for the diagnosis of liver cell dysplasia included cytoplasmic and nuclear enlargement, nuclear pleomorphism together with prominent nucleoli, hyperchromasia and multinucleation. The cytologic features of liver cell dysplasia strikingly mimic hepatocellular carcinoma. From this study, the foci or areas of liver cell dysplasia arising within the liver cell adenomas appear to be the missing link responsible for the transformation of liver cell adenoma to carcinoma. It is believed that liver cell adenomas are not premalignant and may undergo reversible change after withdrawal of causative agents, whereas liver cell dysplasia is an irreversible, premalignant change and will eventually progress to hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712664     DOI: 10.1002/1097-0142(19910715)68:2<341::aid-cncr2820680223>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Malignant transformation of hepatic adenoma with recurrence after resection.

Authors:  Kenneth A Larson; Sharon M Weber; Yuman Fong; Leslie H Blumgart
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

Review 2.  [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma].

Authors:  P Flemming; U Lehmann; D Steinemann; H Kreipe; L Wilkens
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

Review 3.  Hepatic neoplasia: reflections and ruminations.

Authors:  K Aterman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 4.  Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases.

Authors:  Jan H M B Stoot; Robert J S Coelen; Mechteld C De Jong; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

Review 5.  Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis.

Authors:  Shahid M Hussain; Indra C van den Bos; Roy S Dwarkasing; Jan-Willem Kuiper; Jan den Hollander
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 5.315

Review 6.  [Surgical therapy of benign liver tumors].

Authors:  M Loss; C Zülke; A Obed; O Stöltzing; H J Schlitt
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

7.  Oral contraceptives and primary liver cancer among young women.

Authors:  A W Hsing; R N Hoover; J K McLaughlin; H T Co-Chien; S Wacholder; W J Blot; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1992-01       Impact factor: 2.506

8.  Hepatic adenomas in male patients.

Authors:  M Ronald; J Woodfield; J McCall; J Koea
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

9.  The value of laparoscopic liver surgery for solid benign hepatic tumors.

Authors:  Roberto Troisi; Roberto Montalti; Peter Smeets; Jacques Van Huysse; Hans Van Vlierberghe; Isabelle Colle; Steven De Gendt; Bernard de Hemptinne
Journal:  Surg Endosc       Date:  2007-08-21       Impact factor: 4.584

Review 10.  Distinguishing benign from malignant liver tumours.

Authors:  Jay P Heiken
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.